EWTX Edgewise Therapeutics Inc

Price (delayed)

$41.05

Market cap

$4.46B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.86

Enterprise value

$4.39B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 5
Highlights
Edgewise Therapeutics's debt has decreased by 18% YoY and by 5% from the previous quarter
The quick ratio has contracted by 44% YoY and by 28% from the previous quarter
The net income is down by 31% year-on-year and by 12% since the previous quarter

Key stats

What are the main financial stats of EWTX

EWTX stock price

How has the Edgewise Therapeutics stock price performed over time
Intraday
-7.77%
1 week
-9.66%
1 month
-7.08%
1 year
172.03%
YTD
65.42%
QTD
1.03%

Financial performance

How have Edgewise Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$218.9M
Net income
-$197.22M
Gross margin
N/A
Net margin
N/A
The net income is down by 31% year-on-year and by 12% since the previous quarter
The operating income has declined by 25% year-on-year and by 10% since the previous quarter

Price vs fundamentals

How does EWTX's price correlate with its fundamentals

Growth

What is Edgewise Therapeutics's growth rate over time

Valuation

What is Edgewise Therapeutics stock price valuation
P/E
N/A
P/B
9.86
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 20% YoY and by 11% QoQ
The P/B is 72% more than the last 4 quarters average of 6.2
Edgewise Therapeutics's equity has decreased by 24% YoY and by 9% from the previous quarter

Efficiency

How efficient is Edgewise Therapeutics business performance
EWTX's ROIC is down by 30% YoY and by 23% QoQ
EWTX's ROA is down by 27% year-on-year and by 19% since the previous quarter
Edgewise Therapeutics's ROE has decreased by 27% YoY and by 20% from the previous quarter

Dividends

What is EWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EWTX.

Financial health

How did Edgewise Therapeutics financials performed over time
The quick ratio has contracted by 44% YoY and by 28% from the previous quarter
EWTX's current ratio is down by 44% year-on-year and by 28% since the previous quarter
Edgewise Therapeutics's debt is 99% less than its equity
Edgewise Therapeutics's equity has decreased by 24% YoY and by 9% from the previous quarter
Edgewise Therapeutics's debt has decreased by 18% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.